(Q41188370)

28 September 2017

1 reference

title

Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction (English)

1 reference

28 September 2017

S Noble

1

1 reference

28 September 2017

D McTavish

series ordinal

2

1 reference

28 September 2017

publication date

1 October 1996

1 reference

28 September 2017

1 reference

28 September 2017

volume

52

1 reference

28 September 2017

issue

4

1 reference

28 September 2017

page(s)

589-605

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199652040-00012

28 September 2017

exact match

0 references

cites work

More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators

1 reference

12 December 2020

Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats

1 reference

12 December 2020

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

12 December 2020

In vitro stability of a tissue-type plasminogen activator mutant, BM 06.022, in human plasma

1 reference

12 December 2020

Canadian Consensus Conference on Coronary Thrombolysis--1994 recommendations. National Health Research and Development Program

1 reference

12 December 2020

Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction

1 reference

12 December 2020

Bolus Application of a Novel Recombinant Plasminogen Activator in Acute Myocardial Infarction Patients: Pharmacokinetics and Effects on the Hemostatic System

1 reference

12 December 2020

Uptake, internalization and degradation of the novel plasminogen activator reteplase (BM 06.022) in the rat

1 reference

12 December 2020

Differential fibrinolytic properties of the recombinant plasminogen activator BM 06.022 in human plasma and blood clot systems in vitro

1 reference

12 December 2020

Recombinant tissue-type plasminogen activator: current concepts and guidelines for clinical use in acute myocardial infarction. Part I.

1 reference

12 December 2020

Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis

1 reference

12 December 2020

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

1 reference

12 December 2020

Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics

1 reference

12 December 2020

Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thromb

1 reference

12 December 2020

The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction

1 reference

12 December 2020

Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli

1 reference

12 December 2020

Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis

1 reference

12 December 2020

Coronary thrombolysis

1 reference

12 December 2020

Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German Recombinant Plasminogen Activator Study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Kranken

1 reference

12 December 2020

Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)

1 reference

12 December 2020

Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis

1 reference

12 December 2020

Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats

1 reference

12 December 2020

Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers

1 reference

12 December 2020

Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent

1 reference

12 December 2020

Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction.

1 reference

12 December 2020

Guidelines for the use of thrombolytic therapy. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology.

1 reference

12 December 2020

Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction.

1 reference

12 December 2020

Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers.

1 reference

12 December 2020

Pharmacokinetic properties of an Escherichia-coli-produced recombinant plasminogen activator (BM 06.022) in rabbits

1 reference

12 December 2020

Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction

1 reference

12 December 2020

Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators

1 reference

12 December 2020

Cost effectiveness of thrombolytic treatment for myocardial infarction: comparison of anistreplase, alteplase and streptokinase in 270 patients treated within 4 hours

1 reference

12 December 2020

Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers

1 reference

12 December 2020

Coronary Thrombolytic Properties of a Novel Recombinant Plasminogen Activator (BM 06.022) in a Canine Model

1 reference

12 December 2020

Thrombolytic Agents in Development

1 reference

12 December 2020

Thrombolytic therapy for acute myocardial infarction. A review

1 reference

12 December 2020

Fibrinogenolysis and Fibrinolysis with Tissue Plasminogen Activator, Urokinase, Streptokinase-Activated Human Globulin, and Plasmin

1 reference

12 December 2020

Mapping of the catalytic site of CHO‐t‐PA and the t‐PA variant BM 06.022 by synthetic inhibitors and substrates

1 reference

12 December 2020

Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin

1 reference

12 December 2020

The open-artery theory is alive and well--again

1 reference

12 December 2020

Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collabo

1 reference

12 December 2020

Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022

1 reference

12 December 2020

10.2165/00003495-199652040-00012

Identifiers

DOI

1 reference

Dimensions Publication ID

28 September 2017

1050156425

0 references

1 reference